Ozempic fattens Commonwealth coffers – slightly

Ozempic manufacturer, Novo Nordisk’s tax bill more than doubled in the 2021/22 financial year, data from the Australian Taxation Office (ATO) reveals  Surging demand for Novo Nordisk’s diabetes medication, Ozempic (semaglutide), for off-label use as a weight-loss wonder drug, appears to be behind a $100 million jump in the firm’s total income in Australia.